MGI Pharma Articles
Eisai exercises option to buy AkaRx, for $255, along with rights to thrombocytopenia drug AKR-501
21 December 2009
Eisai returns to profit after MGI acquisition
1 June 2009
Japan stock market week to May 18, 2009
19 May 2009
Eisai profit down 38% on MGI acquisition
16 February 2009
Japanese stock prices week to Feb 2, 2009
9 February 2009
Japan majors hope to bolster lagging shares
15 December 2008
Eisai profit down 27% on MGI acquisition
24 November 2008
Japan stock market week to Nov 3, 2008
10 November 2008
Shionogi buys US firm Sciele for $1.1B
8 September 2008
Japan stock market week to Aug 11, 2008
18 August 2008
Japan stock market week to July 28, 2008
4 August 2008
Japan stock market week to July 14, 2008
21 July 2008
Daiichi Sankyo in deal to control Ranbaxy
16 June 2008
Eisai's fiscal 2007 hit by MGI Pharma buy
2 June 2008
Japan stock market week to May 19, 2008
26 May 2008
Japan stock market week to Aril 21, 2008
28 April 2008
Japanese drug firms adapting for growth
14 April 2008
Japan stock market week to March 10, 2008
17 March 2008
Eisai/MGI's Aloxi gets expanded indication
10 March 2008
Japanese pharma companies are steadily penetrating global markets
25 February 2008
Japan stock market week to February 4 , 2008
14 February 2008
Eisai completes $3.9B MGI Pharma buy
4 February 2008
Japan stock market week to Jan 21, 2008
28 January 2008
Positive data on MGI Pharma's Gliadel
28 January 2008
US FTC clears Eisai's buy of MGI Pharma
21 January 2008
FDA accepts MGI's Aquavan NDA
24 December 2007
Japan stock market week to Dec 10, 2007
17 December 2007
MGI Pharma leaps on hiring advisors
10 December 2007
AkaRx and MGI close AKR-501 deal
22 October 2007
MGI Pharma submits Aquavan NDA in USA
8 October 2007
MGI forecasts $1B peak US sales for novel thrombocytopenia drug AKR-501
10 September 2007
MGI and Helsinn submit Aloxi sNDA
14 May 2007
MGI's 1st-qtr 2007 net income rises to $83.2M
30 April 2007
MGI's Aquavan achieves Ph III efficacy endpoint
26 March 2007
MGI's 4th-qtr 2006 net loss narrows to $19.6M
19 February 2007
MGI/Helsinn's Aloxi meets Ph III endpoints
22 December 2006
J&Js 3rd-qtr profit rises 8.7% to $2.76B
23 October 2006
"Approvable" letter for MGI's Saforis
23 October 2006
Actavis launches pilocarpine 7.5mg in USA
11 September 2006
Medicure acquires US rights to Aggrastat
14 August 2006
EMEA orphan status for MGI's Dacogen
7 August 2006
Industry bodies oppose annual revision of Japan
7 August 2006
MGI Pharma moves into loss for 2nd-qtr
24 July 2006
MGI Pharma debuts Dacogen inj in USA
5 June 2006
FDA approves Dacogen for MDS
8 May 2006
MGI submits Saforis NDA to US FDA
24 April 2006
FDA OKs IMPAX' generic Salagen
10 April 2006
MGI Pharma initiates Ph III Aquavan program
27 March 2006
FDA accepts Dacogen NDA as complete response
9 January 2006
Supergen/MGI to enter Dacogen for new indications
19 December 2005
Stock Commentary - Tokyo week to Sept 5
12 September 2005
UPDATE: MGI Pharma makes $178M bid for Guilford, plus assuming $69.4M convertible debt
1 August 2005
MGI Pharma buys Guilford in $178M deal
25 July 2005
MGI reports 241% 1st qtr revenue jump
25 April 2005
Alpharma debuts authorized generic Salagen
28 February 2005
James Hawley joins MGI Pharma s senior VP
7 February 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Helsinn and Kable in Aloxi marketing deal
17 January 2005
FDA accepts Dacogen NDA for review
10 January 2005
MGI/SuperGen's Dacogen filed in USA
8 November 2004
MGI's 3rd-qtr losses rocket on acquisitions
25 October 2004
MGI/SuperGen's Dacogen filed in EU
11 October 2004
MGI Pharma and SuperGen close deal
27 September 2004
MGI and SuperGen sign deal for Dacogen
13 September 2004
MGI goes on $82M spending spree
6 September 2004
MGI Pharma's 2nd-qtr sales rocket to $46.9M
26 July 2004
MGI and Alpharma in Kadian promotion deal
19 July 2004
MGI Pharma sees 1st-qtr sales surge 298%
19 April 2004
MGI Pharma places $200M of notes
1 March 2004
New Chemical Entities in 2003
19 January 2004
MGI Pharma prices $146.6M offering
18 August 2003
MGI Pharma offering 4 million shares
4 August 2003
MGI Pharma/Helsinn's Aloxi gets US approval
4 August 2003
MGI posts LPS of $0.49 for 2nd qtr
29 July 2002
MGI tests novel combination in GI tumors
22 July 2002
MGI to file nausea drug after FDA meeting
13 May 2002
MGI hit hard as cancer drug trial is stopped
22 April 2002
BB licenses cancer drug from MethylGene
18 February 2002
MGI and MethylGene to start MG98 AML study
4 February 2002
MGI Pharma raises $31 million
2 November 2001
Epigenomics and MethylGene in cancer trial collaboration
1 November 2001
MGI expands Phase II ovarian cancer trial
12 October 2001
MGI and MethylGene begin kidney cancer trial
23 August 2001
MGI initiates Phase I irofulven/Gemzar trial
21 June 2001
MGI's irofulven in Ph II for sarcoma
10 May 2001
MGI starts new prostate cancer trial
17 April 2001
MGI buys Hexalen from MedImmune
15 November 2000
MGI Pharma
16 October 2000
MGI Pharma appoints CMO
14 September 2000
MGI Pharma completes 1 million share placement
1 June 2000
Promise with MGI Pharma's irufulven?
24 November 1999
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
